Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial

1Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53. doi: 10.1002/ijc.31937 Ferlay J Colombet M Soerjomataram I Mathers C Parkin DM Pineros M et al Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int J Cancer 2019 144 1941 53 10.1002/ijc.3193730350310Open DOISearch in Google Scholar

2Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424. doi: 10.3322/caac.21492 Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 394 424 10.3322/caac.2149230207593Open DOISearch in Google Scholar

3Yousef AJA. Male breast cancer: epidemiology and risk factors. Semin Oncol 2017; 44:. 267-72. doi: 10.1053/j.seminoncol.2017.11.002 Yousef AJA Male breast cancer: epidemiology and risk factors Semin Oncol 2017 44 267 72 10.1053/j.seminoncol.2017.11.00229526255Open DOISearch in Google Scholar

4Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med 2017; 4: 227. doi: 10.3389/fmed.2017.00227 Turashvili G Brogi E Tumor heterogeneity in breast cancer Front Med 2017 4 227 10.3389/fmed.2017.00227572704929276709Open DOISearch in Google Scholar

5Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev 2018; 27: 619-26. doi: 10.1158/1055-9965.EPI-17-0627 Howlader N Cronin KA Kurian AW Andridge R Differences in breast cancer survival by molecular subtypes in the United States Cancer Epidemiol Biomarkers Prev 2018 27 619 26 10.1158/1055-9965.EPI-17-062729593010Open DOISearch in Google Scholar

6National Institute for Health and Care Excellence (NICE). Advanced breast cancer: diagnosis and treatment CG81. Updated 2017. [Internet]. [cited 2022 Jan 15]. Available at: https://www.nice.org.uk/guidance/cg81 National Institute for Health and Care Excellence (NICE) Advanced breast cancer: diagnosis and treatment CG81 Updated 2017 [Internet]. [cited 2022 Jan 15]. Available at https://www.nice.org.uk/guidance/cg81Search in Google Scholar

7Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623-49. doi: 10.1016/j.annonc.2020.09.010 Cardoso F Paluch-Shimon S Senkus E Curigliano G Aapro MS Andre F et al 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann Oncol 2020 31 1623 49 10.1016/j.annonc.2020.09.010751044932979513Open DOISearch in Google Scholar

8Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16: 310-20. doi: 10.6004/jnccn.2018.0012 Gradishar WJ Anderson BO Balassanian R Blair SL Burstein HJ Cyr A et al Breast cancer, version 4.2017, NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw 2018 16 310 20 10.6004/jnccn.2018.001229523670Open DOISearch in Google Scholar

9Telli ML, Gradishar WJ, Ward JH. NCCN Guidelines updates: breast cancer. J Natl Compr Canc Netw 2019; 17: 552-5. doi: 10.6004/jnccn.2019.5006 Telli ML Gradishar WJ Ward JH NCCN Guidelines updates: breast cancer J Natl Compr Canc Netw 2019 17 552 5 10.6004/jnccn.2019.500631117035Open DOISearch in Google Scholar

10Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016; 388: 2997-3005. doi: 10.1016/S0140-6736(16)32389-3 Robertson JFR Bondarenko IM Trishkina E Dvorkin M Panasci L Manikhas A et al Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Lancet 2016 388 2997 3005 10.1016/S0140-6736(16)32389-327908454Open DOISearch in Google Scholar

11Yamamoto-Ibusuki M, Arnedos M, Andre F. Targeted therapies for ER+/ HER2- metastatic breast cancer. BMC Med 2015; 13: 137. doi: 10.1186/s12916-015-0369-5 Yamamoto-Ibusuki M Arnedos M Andre F Targeted therapies for ER+/ HER2- metastatic breast cancer BMC Med 2015 13 137 10.1186/s12916-015-0369-5446218426059247Open DOISearch in Google Scholar

12Araki K, Miyoshi Y. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer 2018; 25: 392-401. doi: 10.1007/s12282-017-0812-x Araki K Miyoshi Y Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer Breast Cancer 2018 25 392 401 10.1007/s12282-017-0812-x29086897Open DOISearch in Google Scholar

13AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol 2018; 25(Suppl 1): S18-27. doi: 10.3747/co.25.3752 AlFakeeh A Brezden-Masley C Overcoming endocrine resistance in hormone receptor-positive breast cancer Curr Oncol 2018 25 Suppl 1 S18 27 10.3747/co.25.3752600175629910644Open DOISearch in Google Scholar

14Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 2016; 45: 129-38. doi: 10.1016/j.ctrv.2016.03.002 Hamilton E Infante JR Targeting CDK4/6 in patients with cancer Cancer Treat Rev 2016 45 129 38 10.1016/j.ctrv.2016.03.00227017286Open DOISearch in Google Scholar

15Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375: 1925-36. doi: 10.1056/NEJMoa1607303 Finn RS Martin M Rugo HS Jones S Im SA Gelmon K et al Palbociclib and letrozole in advanced breast cancer N Engl J Med 2016 375 1925 36 10.1056/NEJMoa160730327959613Open DOISearch in Google Scholar

16Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017; 35: 2875-84. doi: 10.1200/JCO.2017.73.7585 Sledge GW Jr Toi M Neven P Sohn J Inoue K Pivot X et al MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol 2017 35 2875 84 10.1200/JCO.2017.73.758528580882Open DOISearch in Google Scholar

17Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375: 1738-48. doi: 10.1056/NEJMoa1609709 Hortobagyi GN Stemmer SM Burris HA Yap YS Sonke GS Paluch-Shimon S et al Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 2016 375 1738 48 10.1056/NEJMoa160970927717303Open DOISearch in Google Scholar

18Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res 2017; 23: 3251-62. doi:10.1158/1078-0432.Ccr-16-3157 Tripathy D Bardia A Sellers WR Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors Clin Cancer Res 2017 23 3251 62 10.1158/1078-0432.Ccr-16-3157Open DOISearch in Google Scholar

19Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018; 29: 15417. doi: 10.1093/annonc/mdy155 Hortobagyi GN Stemmer SM Burris HA Yap YS Sonke GS Paluch-Shimon S et al Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 2018 29 15417 10.1093/annonc/mdy15529718092Open DOISearch in Google Scholar

20Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-72. doi: 10.1200/JCO.2018.78.9909 Slamon DJ Neven P Chia S Fasching PA De Laurentiis M Im SA et al Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 J Clin Oncol 2018 36 2465 72 10.1200/JCO.2018.78.990929860922Open DOISearch in Google Scholar

21Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-15. doi: 10.1016/S1470-2045(18)30292-4 Tripathy D Im SA Colleoni M Franke F Bardia A Harbeck N et al Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Lancet Oncol 2018 19 904 15 10.1016/S1470-2045(18)30292-429804902Open DOISearch in Google Scholar

22Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022; 386: 942-50. doi: 10.1056/NEJMoa2114663 Hortobagyi GN Stemmer SM Burris HA Yap YS Sonke GS Hart L et al Overall survival with ribociclib plus letrozole in advanced breast cancer N Engl J Med 2022 386 942 50 10.1056/NEJMoa211466335263519Open DOISearch in Google Scholar

23Tripathy D, Im S, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. [Abstract PD2-04]. San Antonio Breast Cancer Virtual Symposium, San Antonio, Texas, USA, December 8-12, 2020. doi: 10.1158/1538-7445.SABCS20-PD2-04 Tripathy D Im S Colleoni M Franke F Bardia A Harbeck N et al Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. [Abstract PD2-04]. San Antonio Breast Cancer Virtual Symposium San Antonio, Texas, USA December 8-12 2020 10.1158/1538-7445.SABCS20-PD2-04Open DOISearch in Google Scholar

24Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2020; 382: 514-24. doi: 10.1056/NEJMoa1911149 Slamon DJ Neven P Chia S Fasching PA De Laurentiis M Im SA et al Overall survival with ribociclib plus fulvestrant in advanced breast cancer N Engl J Med 2020 382 514 24 10.1056/NEJMoa191114931826360Open DOISearch in Google Scholar

25DeLaurentiis M, Neven P, Jerusalem GHM, Bachelot TD, Jacot W, Dent SF, et al. Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial. [Abstract 1056P]. J Clin Oncol 2018; 36: 1056. doi: 10.1200/JCO.2018.36.15_suppl.1056 DeLaurentiis M Neven P Jerusalem GHM Bachelot TD Jacot W Dent SF et al Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial [Abstract 1056P]. J Clin Oncol 2018 36 1056 10.1200/JCO.2018.36.15_suppl.1056Open DOISearch in Google Scholar

26De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, et al. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat 2021; 189: 68999. doi: 10.1007/s10549-021-06334-0 De Laurentiis M Borstnar S Campone M Warner E Bofill JS Jacot W et al Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population Breast Cancer Res Treat 2021 189 68999 10.1007/s10549-021-06334-0850529134414532Open DOISearch in Google Scholar

27Bilgin B, Sendur MAN, Sener Dede D, Akinci MB, Yalcin B. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. Curr Med Res Opin 2017; 33: 1559-69. doi: 10.1080/03007995.2017.1348344 Bilgin B Sendur MAN Sener Dede D Akinci MB Yalcin B A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer Curr Med Res Opin 2017 33 1559 69 10.1080/03007995.2017.134834428657360Open DOISearch in Google Scholar

28Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res 2016; 18: 17. doi: 10.1186/s13058-015-0661-5 Finn RS Aleshin A Slamon DJ Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers Breast Cancer Res 2016 18 17 10.1186/s13058-015-0661-5474689326857361Open DOISearch in Google Scholar

29Verma S, O’Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, et al. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2. Breast Cancer Res Treat 2018; 170: 535-45. doi:10.1007/s10549-018-4769-z Verma S O’Shaughnessy J Burris HA Campone M Alba E Chandiwana D et al Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 Breast Cancer Res Treat 2018 170 535 45 10.1007/s10549-018-4769-z602253129654415Open DOISearch in Google Scholar